Ondansetron Administration for Nausea and Vomiting Management

Dosing Guidelines

For adults experiencing nausea and vomiting, the National Comprehensive Cancer Network recommends ondansetron can be administered intramuscularly at a dose of 4-8 mg 1
The intramuscular route is an effective alternative when oral or intravenous administration is not feasible due to ongoing vomiting or lack of intravenous access, as suggested by the National Comprehensive Cancer Network 1

For breakthrough nausea and vomiting, the National Comprehensive Cancer Network suggests IM ondansetron can be administered as needed 2

In elderly patients, the American Gastroenterological Association notes that no specific dose adjustment is required for IM administration 3
In pediatric patients >4 years of age, the Infectious Diseases Society of America recommends ondansetron can be safely administered intramuscularly at 0.15 mg/kg 4
For patients with hepatic impairment, the American Gastroenterological Association advises caution should be exercised, though specific dose adjustments for IM administration are not well established 3

The American Gastroenterological Association explains that ondansetron belongs to the 5-HT3 receptor antagonist class and works by blocking serotonin receptors in the chemoreceptor trigger zone and vagal afferents 3
The National Comprehensive Cancer Network suggests that for persistent nausea and vomiting despite ondansetron administration, consider adding dexamethasone which has been shown to improve antiemetic efficacy 1

The National Comprehensive Cancer Network notes that for patients who fail to respond to ondansetron alone, combination therapy with dexamethasone may provide enhanced antiemetic effect 1